Compare LOOP & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOOP | NXTC |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 46.6M |
| IPO Year | N/A | 2019 |
| Metric | LOOP | NXTC |
|---|---|---|
| Price | $1.02 | $13.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 73.4K | 37.5K |
| Earning Date | 01-15-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,112,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $41.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10901.98 | N/A |
| 52 Week Low | $0.85 | $2.69 |
| 52 Week High | $2.29 | $15.74 |
| Indicator | LOOP | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 60.51 |
| Support Level | $0.95 | $12.79 |
| Resistance Level | $1.04 | $14.65 |
| Average True Range (ATR) | 0.07 | 0.98 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 97.14 | 73.15 |
Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.